



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

July 2024





© 2024 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to people living with HIV throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

July 2024

N = 7721



Health Authority	Male	Female	All
FRASER	1601	489	2090
INTERIOR	488	119	607
NORTHERN	172	86	258
VANCOUVER COASTAL	3249	448	3697
VANCOUVER ISLAND	879	172	1051
	6389	1314	7703
		Unknown/not stated:	18
		Total:	7721

Definitions:

On antiretroviral therapy defined as being on treatment in the current month


Unknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male & Female refer to Sex at birth





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (July 2019 - July 2024)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (July 2019 - July 2024)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (July 2019 - July 2024)






1.5 BC-CfE Enrolment: New Antiretroviral Participants (July 2019 - July 2024)






1.6 Percent Distribution of Active Participants by CD4 Count
(July 2019 - July 2024)






1.7 Percent Distribution of Inactive Participants by CD4 Count (July 2019 - July 2024)






1.8 Active and Inactive Participants (July 2019 - July 2024)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (July 2019 - July 2024)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (July 2019 - July 2024)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(July 2019 - July 2024)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (July 2019 - July 2024)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(July 2019 - July 2024)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (July 2019 - July 2024)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(July 2019 - July 2024)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (July 2019 - July 2024)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first ARV Therapy by INGREDIENT

(July 2019 - July 2024)






1.18 Baseline CD4 for Antiretroviral First Starts (June 2019 - June 2024)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (July 2019 - July 2024)






1.20 Cumulative Resistance Testing Results by Resistance Category (July 2019 - July 2024)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (July 2019 - July 2024)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2024
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	33	3	0	3	0		3	<40	3
1988	33	4	0	4	1	480	4	<40	4
1989	31	46	1	47	18	510	45	<40	3
1990	29	47	1	48	23	570	47	<40	3
1991	30	35	3	38	14	525	36	<40	3
1992	30	49	4	53	20	675	49	<40	3
1993	29	109	14	123	61	550	115	<40	3
1994	27	64	11	75	39	620	70	<40	3
1995	27	117	19	136	69	570	125	<40	3
1996	25	294	45	339	166	575	297	<40	3
1997	23	249	28	277	149	610	257	<40	3
1998	23	171	35	206	108	530	183	<40	3
1999	23	143	38	181	105	570	163	<40	3
2000	23	108	26	134	70	615	121	<40	3
2001	22	107	23	130	67	630	118	<40	3
2002	21	110	19	129	68	555	119	<40	3
2003	21	130	25	155	84	570	143	<40	3
2004	20	137	37	174	98	655	156	<40	3
2005	19	166	43	209	124	685	195	<40	3
2006	18	156	36	192	103	660	172	<40	3
2007	17	220	39	259	158	700	242	<40	3
2008	16	257	57	314	188	645	282	<40	3
2009	15	285	58	343	187	630	298	<40	3
2010	14	243	65	308	174	655	272	<40	3
2011	13	305	67	372	202	715	319	<40	3
2012	12	260	62	322	176	720	286	<40	3
2013	11	240	62	302	180	728	276	<40	3
2014	10	258	42	300	154	740	269	<40	3
2015	9	249	43	292	163	680	263	<40	3
2016	8	225	48	273	160	680	238	<40	3
2017	7	193	34	227	133	680	201	<40	3
2018	6	167	43	210	123	760	186	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2024
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
2019	5	207	42	249	160	740	220	<40	3
2020	4	154	51	205	133	750	174	<40	3
2021	3	179	32	211	120	645	191	<40	3
2022	2	241	47	288	193	690	268	<40	3
2023	1	270	64	334	213	600	312	<40	3
2024	0	191	47	238	207	550	232	<40	3
Total:		6389	1311	7700					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2023	7581	793	2051	<40	1320	650
FEB-2023	7521	807	1727	<40	1020	630
MAR-2023	7548	803	1974	<40	1215	640
APR-2023	7553	796	1761	<40	1084	630
MAY-2023	7592	786	1933	<40	1238	645
JUN-2023	7599	787	1841	<40	1098	640
JUL-2023	7577	806	1747	<40	1053	620
AUG-2023	7600	806	1814	<40	1041	630
SEP-2023	7609	797	1775	<40	1065	650
OCT-2023	7611	803	1887	<40	1151	620
NOV-2023	7613	798	1854	<40	1095	650
DEC-2023	7604	801	1549	<40	913	640
JAN-2024	7643	792	1973	<40	1166	650
FEB-2024	7646	785	1772	<40	1028	620
MAR-2024	7635	792	1680	<40	978	650
APR-2024	7671	786	1943	<40	1211	660
MAY-2024	7692	787	1880	<40	1050	660
JUN-2024	7695	787	1695	<40	980	650
JUL-2024	7721	789	1803	<40	979	610

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2023	734	276	63	<40	45	550
FEB-2023	787	230	66	<40	53	550
MAR-2023	756	242	78	<40	56	512
APR-2023	760	218	66	<40	47	560
MAY-2023	726	239	65	<40	48	430
JUN-2023	708	200	57	<40	39	460
JUL-2023	739	182	68	<40	50	565
AUG-2023	738	188	63	<40	40	595
SEP-2023	725	207	55	<40	41	540
OCT-2023	734	210	60	<40	46	625
NOV-2023	742	203	65	<40	46	515
DEC-2023	751	192	47	<40	35	473
JAN-2024	708	219	67	<40	49	520
FEB-2024	707	230	59	<40	42	605
MAR-2024	721	199	66	<40	45	600
APR-2024	702	228	67	<40	55	560
MAY-2024	699	219	57	<40	40	555
JUN-2024	715	192	60	<40	37	460
JUL-2024	706	197	56	<40	29	640

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2023	7550	734	20	10	193	143	40	14767
FEB-2023	7505	787	10	11	158	204	-45	14791
MAR-2023	7532	756	15	21	197	176	27	14825
APR-2023	7531	760	13	11	176	169	-1	14854
MAY-2023	7575	726	7	15	205	165	44	14898
JUN-2023	7577	708	14	17	168	165	3	14933
JUL-2023	7555	739	11	11	164	181	-22	14964
AUG-2023	7577	738	11	13	217	192	22	15009
SEP-2023	7579	725	14	5	179	163	2	15029
OCT-2023	7580	734	18	10	170	159	1	15060
NOV-2023	7579	742	17	9	182	172	-1	15096
DEC-2023	7575	751	14	13	169	169	-4	15129
JAN-2024	7614	708	16	11	204	159	39	15161
FEB-2024	7619	707	17	11	182	165	5	15193
MAR-2024	7615	721	12	15	181	185	-4	15228
APR-2024	7648	702	17	20	198	167	33	15274
MAY-2024	7672	699	11	16	191	171	24	15311
JUN-2024	7682	715	5	24	170	178	10	15352
JUL-2024	7700	706	13	10	181	159	18	15383

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2023	721	6371	445	44	7581	9.51%	84.04%	5.87%	0.58%	100.00%
FEB-2023	735	6318	429	39	7521	9.77%	84.00%	5.70%	0.52%	100.00%
MAR-2023	750	6312	445	41	7548	9.94%	83.62%	5.90%	0.54%	100.00%
APR-2023	765	6307	440	41	7553	10.13%	83.50%	5.83%	0.54%	100.00%
MAY-2023	802	6314	435	41	7592	10.56%	83.17%	5.73%	0.54%	100.00%
JUN-2023	821	6299	438	41	7599	10.80%	82.89%	5.76%	0.54%	100.00%
JUL-2023	844	6253	440	40	7577	11.14%	82.53%	5.81%	0.53%	100.00%
AUG-2023	866	6240	448	46	7600	11.39%	82.11%	5.89%	0.61%	100.00%
SEP-2023	881	6250	432	46	7609	11.58%	82.14%	5.68%	0.60%	100.00%
OCT-2023	899	6238	433	41	7611	11.81%	81.96%	5.69%	0.54%	100.00%
NOV-2023	920	6211	441	41	7613	12.08%	81.58%	5.79%	0.54%	100.00%
DEC-2023	938	6192	434	40	7604	12.34%	81.43%	5.71%	0.53%	100.00%
JAN-2024	954	6215	432	42	7643	12.48%	81.32%	5.65%	0.55%	100.00%
FEB-2024	974	6197	436	39	7646	12.74%	81.05%	5.70%	0.51%	100.00%
MAR-2024	993	6158	440	44	7635	13.01%	80.65%	5.76%	0.58%	100.00%
APR-2024	1003	6185	437	46	7671	13.08%	80.63%	5.70%	0.60%	100.00%
MAY-2024	1026	6192	435	39	7692	13.34%	80.50%	5.66%	0.51%	100.00%
JUN-2024	1036	6188	428	43	7695	13.46%	80.42%	5.56%	0.56%	100.00%
JUL-2024	1064	6187	433	37	7721	13.78%	80.13%	5.61%	0.48%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	6 17%	2971 40%	1 3%	2147 29%	1 3%	16 0%	23 66%	3491 47%	8 23%	1095 15%	29 83%	4465 60%
FEB-2023	3 13%	2944 40%	1 4%	2097 28%	0 0%	17 0%	18 75%	3502 47%	3 13%	1065 14%	21 88%	4446 60%
MAR-2023	2 6%	2936 40%	2 6%	2071 28%	0 0%	15 0%	27 79%	3551 48%	5 15%	1051 14%	32 94%	4476 60%
APR-2023	3 10%	2948 40%	1 3%	2067 28%	0 0%	15 0%	24 83%	3550 48%	3 10%	1030 14%	26 90%	4469 60%
MAY-2023	10 24%	2940 39%	4 10%	2043 27%	1 2%	16 0%	30 71%	3598 48%	3 7%	1040 14%	32 76%	4513 61%
JUN-2023	4 12%	2934 39%	1 3%	2008 27%	0 0%	14 0%	26 76%	3655 49%	4 12%	1002 13%	30 88%	4533 61%
JUL-2023	5 16%	2917 39%	1 3%	1966 26%	0 0%	14 0%	25 81%	3678 49%	2 6%	985 13%	26 84%	4530 61%
AUG-2023	4 9%	2909 39%	1 2%	1935 26%	0 0%	14 0%	34 76%	3717 50%	9 20%	969 13%	41 91%	4561 61%
SEP-2023	2 10%	2902 39%	1 5%	1910 26%	0 0%	13 0%	15 75%	3746 50%	3 15%	954 13%	18 90%	4578 61%
OCT-2023	2 6%	2905 39%	1 3%	1895 25%	0 0%	14 0%	23 74%	3766 50%	6 19%	936 13%	29 94%	4573 61%
NOV-2023	1 3%	2892 39%	0 0%	1866 25%	0 0%	15 0%	27 77%	3783 51%	7 20%	919 12%	34 97%	4585 61%
DEC-2023	6 18%	2875 39%	4 12%	1831 25%	0 0%	13 0%	25 76%	3820 51%	3 9%	896 12%	27 82%	4595 62%
JAN-2024	9 29%	2881 38%	8 26%	1831 24%	0 0%	13 0%	21 68%	3867 52%	2 6%	890 12%	22 71%	4634 62%
FEB-2024	7 22%	2867 38%	4 13%	1795 24%	0 0%	13 0%	22 69%	3896 52%	3 9%	863 12%	25 78%	4641 62%
MAR-2024	2 6%	2844 38%	0 0%	1759 23%	0 0%	13 0%	30 86%	3927 52%	3 9%	843 11%	33 94%	4656 62%
APR-2024	10 22%	2844 38%	5 11%	1742 23%	0 0%	13 0%	34 74%	3969 53%	3 7%	843 11%	36 78%	4691 62%
MAY-2024	4 11%	2824 37%	1 3%	1708 23%	0 0%	12 0%	31 84%	4021 53%	2 5%	832 11%	33 89%	4737 63%
JUN-2024	2 5%	2820 37%	2 5%	1694 22%	0 0%	13 0%	35 85%	4052 54%	4 10%	801 11%	39 95%	4743 63%
JUL-2024	4 13%	2816 37%	1 3%	1668 22%	0 0%	13 0%	22 73%	4077 54%	4 13%	801 11%	26 87%	4763 63%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	0 0%	339 25%	1 100%	993 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
FEB-2023	0 0%	321 24%	0 0%	953 73%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
MAR-2023	0 0%	317 24%	1 100%	952 73%	0 0%	42 3%	0 0%	1 0%	0 0%	1 0%
APR-2023	0 0%	305 23%	1 100%	957 74%	0 0%	41 3%	0 0%	1 0%	0 0%	1 0%
MAY-2023	0 0%	303 23%	2 100%	951 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUN-2023	0 0%	294 23%	0 0%	936 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUL-2023	0 0%	283 23%	3 100%	927 74%	0 0%	38 3%	0 0%	1 0%	0 0%	1 0%
AUG-2023	0 0%	276 23%	3 100%	914 75%	0 0%	36 3%	0 0%	0 0%	0 0%	0 0%
SEP-2023	0 0%	271 22%	0 0%	909 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
OCT-2023	1 50%	273 23%	1 50%	893 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
NOV-2023	1 33%	260 22%	2 67%	890 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
DEC-2023	0 0%	248 21%	1 100%	876 76%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
JAN-2024	0 0%	241 21%	3 100%	866 76%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
FEB-2024	0 0%	229 21%	0 0%	852 77%	0 0%	31 3%	0 0%	0 0%	0 0%	0 0%
MAR-2024	0 0%	225 21%	1 100%	840 77%	0 0%	30 3%	0 0%	0 0%	0 0%	0 0%
APR-2024	0 0%	224 21%	3 100%	835 77%	0 0%	31 3%	0 0%	0 0%	0 0%	0 0%
MAY-2024	0 0%	222 20%	1 100%	829 77%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
JUN-2024	1 50%	214 20%	1 50%	814 77%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
JUL-2024	0 0%	216 21%	0 0%	803 76%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	3 43%	192 19%	4 57%	247 25%	0 0%	107 11%	0 0%	255 26%	0 0%	191 19%
FEB-2023	0 0%	202 20%	0 0%	250 25%	0 0%	98 10%	0 0%	249 25%	0 0%	190 19%
MAR-2023	0 0%	209 21%	0 0%	242 25%	0 0%	101 10%	0 0%	246 25%	0 0%	186 19%
APR-2023	1 50%	215 22%	1 50%	232 24%	0 0%	96 10%	0 0%	245 25%	0 0%	187 19%
MAY-2023	1 33%	223 23%	0 0%	232 24%	0 0%	98 10%	0 0%	239 24%	2 67%	187 19%
JUN-2023	0 0%	224 23%	3 75%	228 24%	0 0%	96 10%	0 0%	230 24%	1 25%	180 19%
JUL-2023	0 0%	235 25%	1 100%	222 23%	0 0%	94 10%	0 0%	225 24%	0 0%	178 19%
AUG-2023	0 0%	238 25%	2 100%	222 23%	0 0%	91 10%	0 0%	223 23%	0 0%	182 19%
SEP-2023	0 0%	236 25%	0 0%	218 23%	0 0%	88 9%	1 100%	220 23%	0 0%	177 19%
OCT-2023	0 0%	239 26%	2 100%	216 23%	0 0%	89 10%	0 0%	220 24%	0 0%	173 19%
NOV-2023	0 0%	243 26%	0 0%	209 22%	1 50%	88 9%	0 0%	219 24%	1 50%	173 19%
DEC-2023	1 50%	251 27%	0 0%	205 22%	0 0%	87 9%	0 0%	213 23%	1 50%	176 19%
JAN-2024	0 0%	250 27%	0 0%	200 22%	0 0%	83 9%	0 0%	208 23%	2 100%	181 20%
FEB-2024	0 0%	256 28%	0 0%	192 21%	0 0%	82 9%	0 0%	207 23%	0 0%	182 20%
MAR-2024	0 0%	259 28%	1 100%	190 21%	0 0%	80 9%	0 0%	205 22%	0 0%	181 20%
APR-2024	0 0%	261 29%	0 0%	190 21%	0 0%	82 9%	0 0%	203 22%	0 0%	180 20%
MAY-2024	0 0%	262 29%	0 0%	186 21%	0 0%	80 9%	0 0%	205 23%	0 0%	175 19%
JUN-2024	0 0%	262 29%	0 0%	182 20%	0 0%	79 9%	0 0%	198 22%	0 0%	172 19%
JUL-2024	0 0%	271 30%	0 0%	176 20%	0 0%	78 9%	0 0%	194 22%	1 100%	172 19%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		cabotegravir		dolutegravir		elvitegravir		fostemsavir		maraviroc		raltegravir											
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All										
JAN-2023	23	82%	3016	50%	0	0%	0	0%	5	18%	2492	41%	0	0%	269	4%	0	0%	21	0%	0	0%	302	5%
FEB-2023	18	75%	3040	50%	0	0%	0	0%	6	25%	2476	41%	0	0%	255	4%	0	0%	21	0%	0	0%	288	5%
MAR-2023	25	74%	3084	51%	0	0%	0	0%	5	15%	2482	41%	2	6%	259	4%	0	0%	20	0%	2	6%	291	5%
APR-2023	22	81%	3084	50%	0	0%	0	0%	4	15%	2498	41%	1	4%	258	4%	0	0%	18	0%	0	0%	274	4%
MAY-2023	28	67%	3138	51%	1	2%	3	0%	12	29%	2504	41%	1	2%	250	4%	0	0%	18	0%	0	0%	278	5%
JUN-2023	26	81%	3197	51%	0	0%	5	0%	6	19%	2509	40%	0	0%	248	4%	0	0%	18	0%	0	0%	267	4%
JUL-2023	25	83%	3218	52%	0	0%	5	0%	5	17%	2499	40%	0	0%	247	4%	0	0%	18	0%	0	0%	256	4%
AUG-2023	33	79%	3258	52%	0	0%	7	0%	6	14%	2495	40%	1	2%	245	4%	0	0%	18	0%	2	5%	253	4%
SEP-2023	15	79%	3289	52%	0	0%	8	0%	4	21%	2500	40%	0	0%	238	4%	0	0%	18	0%	0	0%	249	4%
OCT-2023	22	76%	3298	52%	0	0%	7	0%	7	24%	2523	40%	0	0%	241	4%	0	0%	18	0%	0	0%	248	4%
NOV-2023	27	82%	3327	53%	0	0%	9	0%	6	18%	2518	40%	0	0%	233	4%	0	0%	17	0%	0	0%	244	4%
DEC-2023	24	77%	3365	53%	0	0%	13	0%	7	23%	2506	40%	0	0%	226	4%	0	0%	16	0%	0	0%	237	4%
JAN-2024	20	65%	3419	53%	1	3%	16	0%	10	32%	2520	39%	0	0%	224	4%	0	0%	18	0%	0	0%	234	4%
FEB-2024	21	66%	3453	54%	0	0%	15	0%	10	31%	2516	39%	0	0%	219	3%	0	0%	18	0%	1	3%	231	4%
MAR-2024	30	88%	3498	54%	0	0%	17	0%	4	12%	2500	39%	0	0%	220	3%	0	0%	17	0%	0	0%	225	3%
APR-2024	34	76%	3546	55%	0	0%	17	0%	11	24%	2497	38%	0	0%	216	3%	0	0%	18	0%	0	0%	225	3%
MAY-2024	29	78%	3589	55%	0	0%	19	0%	8	22%	2489	38%	0	0%	213	3%	0	0%	15	0%	0	0%	222	3%
JUN-2024	35	88%	3619	55%	0	0%	21	0%	5	13%	2490	38%	0	0%	207	3%	0	0%	17	0%	0	0%	219	3%
JUL-2024	20	65%	3650	55%	1	3%	25	0%	6	19%	2504	38%	4	13%	212	3%	0	0%	17	0%	0	0%	213	3%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Fostemsavir not currently on BC-CfE Formulary





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		IV 3 drugs from IV 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2023	750	9.89	665	8.77	4728	62.37	718	9.47	649	8.56	71	0.94
FEB-2023	715	9.51	665	8.84	4712	62.65	733	9.75	626	8.32	70	0.93
MAR-2023	699	9.26	653	8.65	4735	62.73	748	9.91	644	8.53	69	0.91
APR-2023	704	9.32	653	8.65	4736	62.70	762	10.09	634	8.39	64	0.85
MAY-2023	706	9.30	644	8.48	4752	62.59	800	10.54	627	8.26	63	0.83
JUN-2023	675	8.88	625	8.22	4788	63.01	819	10.78	627	8.25	65	0.86
JUL-2023	662	8.74	626	8.26	4758	62.80	842	11.11	628	8.29	61	0.81
AUG-2023	643	8.46	621	8.17	4773	62.80	864	11.37	632	8.32	67	0.88
SEP-2023	639	8.40	616	8.10	4793	62.99	879	11.55	617	8.11	65	0.85
OCT-2023	615	8.08	612	8.04	4808	63.17	897	11.79	618	8.12	61	0.80
NOV-2023	611	8.03	600	7.88	4799	63.04	918	12.06	624	8.20	61	0.80
DEC-2023	593	7.80	597	7.85	4808	63.23	936	12.31	614	8.07	56	0.74
JAN-2024	583	7.63	585	7.65	4857	63.55	952	12.46	609	7.97	57	0.75
FEB-2024	564	7.38	585	7.65	4861	63.58	971	12.70	609	7.96	56	0.73
MAR-2024	543	7.11	579	7.58	4846	63.47	991	12.98	618	8.09	58	0.76
APR-2024	538	7.01	570	7.43	4885	63.68	1000	13.04	621	8.10	57	0.74
MAY-2024	536	6.97	566	7.36	4905	63.77	1023	13.30	608	7.90	54	0.70
JUN-2024	526	6.84	556	7.23	4917	63.90	1034	13.44	606	7.88	56	0.73
JUL-2024	519	6.72	542	7.02	4941	63.99	1062	13.75	604	7.82	53	0.69

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2023	10	2	2	2	2	2	285
FEB-2023	11	2	2	3	1	3	253
MAR-2023	21	0	0	4	3	11	530
APR-2023	11	1	3	1	1	4	325
MAY-2023	15	2	1	2	5	2	374
JUN-2023	17	2	4	3	2	6	340
JUL-2023	11	1	2	3	2	3	260
AUG-2023	13	2	1	4	2	2	255
SEP-2023	5	1	1	0	0	3	616
OCT-2023	10	0	1	3	2	3	390
NOV-2023	9	1	1	0	2	4	575
DEC-2023	13	1	0	3	0	8	592
JAN-2024	11	2	2	2	1	3	287
FEB-2024	11	1	2	4	2	1	281
MAR-2024	15	3	2	1	2	5	440
APR-2024	20	0	4	6	1	9	364
MAY-2024	16	2	3	3	1	6	320
JUN-2024	24	1	1	10	4	8	360
JUL-2024	10	0	1	3	3	2	374

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2023	12447	3802
FEB-2023	12435	3787
MAR-2023	12442	3786
APR-2023	12417	3752
MAY-2023	12425	3730
JUN-2023	12398	3692
JUL-2023	12425	3715
AUG-2023	12422	3697
SEP-2023	12409	3685
OCT-2023	12393	3661
NOV-2023	12380	3648
DEC-2023	12401	3656
JAN-2024	12410	3664
FEB-2024	12423	3671
MAR-2024	12455	3686
APR-2024	12480	3691
MAY-2024	12489	3688
JUN-2024	12499	3668
JUL-2024	12499	3666

Definitions:


Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7721
Jul-2024

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jul-2024

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant Jul-2024

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant Jul-2024

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jul-2024

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jul-2024

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	5	5	5
	35-49	12	12	7
	50+	31	48	20
	Total HSDA:	48	65	32
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	70	101	50	
OKANAGAN	0-19	*	*	0
	20-34	*	*	34
	35-49	*	*	85
	50+	*	*	232
Total HSDA:	470	633	351	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	232	322	174	
Total HA:		820	1121	607

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	79	80	*
	35-49	191	207	*
	50+	544	828	*
Total HA:		820	1121	607

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	163	226	119
Male	657	895	488

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	607	56	650	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	25	13
	5 years or more	14	10
	<5 years	9	9
	Total HSDA:	48	32
KOOTENAY BOUNDARY	10 years or more	50	34
	5 years or more	11	8
	<5 years	9	8
	Total HSDA:	70	50
OKANAGAN	10 years or more	303	223
	5 years or more	83	59
	<5 years	84	69
	Total HSDA:	470	351
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	141	107
	5 years or more	42	27
	<5 years	49	40
	Total HSDA:	232	174
Total HA:		820	607

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	519	377
5 years or more	150	104
<5 years	151	126
Total HA:	820	607

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	55	100	13	29
KOOTENAY BOUNDARY	76	139	19	41
OKANAGAN	241	1085	53	324
THOMPSON/CARIBOO/SHUSWAP	150	582	27	139
Total:	522	1906	112	533

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	130

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	7
	20-34	45	46	35
	35-49	106	110	69
	50+	274	385	199
	Total HSDA:	432	548	310
FRASER NORTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	1179	1601	904
FRASER SOUTH	0-19	7	7	7
	20-34	138	141	115
	35-49	303	331	243
	50+	652	1001	511
	Total HSDA:	1100	1480	876
Total HA:		2711	3629	2090

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	17	17	17
	20-34	315	321	254
	35-49	777	835	593
	50+	1602	2456	1226
Total HA:		2711	3629	2090

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	646	833	489
Male	2065	2796	1601

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	2090	53	650	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	275	203
	5 years or more	80	47
	<5 years	77	60
	Total HSDA:	432	310
FRASER NORTH	10 years or more	753	562
	5 years or more	212	166
	<5 years	214	176
	Total HSDA:	1179	904
FRASER SOUTH	10 years or more	666	518
	5 years or more	202	150
	<5 years	232	208
	Total HSDA:	1100	876
Total HA:		2711	2090

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1694	1283
	5 years or more	494	363
	<5 years	523	444
Total HA:		2711	2090

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	154	559	33	65
FRASER NORTH	265	1620	37	237
FRASER SOUTH	234	1894	47	517
Total:	653	4073	117	819

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	209
FRASER NORTH	736
FRASER SOUTH	474
Total:	1419

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		368	547
RICHMOND	20-34	33	34	26
	35-49	62	63	48
	50+	128	185	104
	Total HSDA:	223	282	178
VANCOUVER	0-19	8	8	7
	20-34	380	393	282
	35-49	1210	1355	821
	50+	3000	5454	2117
	Total HSDA:	4598	7210	3227
Total HA:		5189	8039	3697

Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
0-19	12	12	11
20-34	444	458	328
35-49	1347	1499	929
50+	3386	6070	2429
Total HA:	5189	8039	3697

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	577	968	448
Male	4612	7071	3249

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3697	56	660	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	258	207
	5 years or more	52	41
	<5 years	58	44
	Total HSDA:	368	292
RICHMOND	10 years or more	122	95
	5 years or more	35	26
	<5 years	66	57
	Total HSDA:	223	178
VANCOUVER	10 years or more	3313	2274
	5 years or more	692	496
	<5 years	593	457
	Total HSDA:	4598	3227
Total HA:		5189	3697

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3693	2576
	5 years or more	779	563
	<5 years	717	558
Total HA:		5189	3697

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	195	565	39	58
RICHMOND	48	331	9	106
VANCOUVER	707	11908	216	5446
Total:	950	12804	264	5610

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	12
RICHMOND	5
VANCOUVER	49
Total:	66

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		367	538
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		143	198
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		844	1208
Total HA:		1354	1944	1051

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	6
	20-34	106	114	71
	35-49	312	348	244
	50+	930	1476	730
Total HA:		1354	1944	1051

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	222	326	172
Male	1132	1618	879

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1051	57	600	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	238	196
	5 years or more	71	49
	<5 years	58	50
	Total HSDA:	367	295
NORTH VANCOUVER ISLAND	10 years or more	104	87
	5 years or more	27	21
	<5 years	12	11
	Total HSDA:	143	119
SOUTH VANCOUVER ISLAND	10 years or more	528	387
	5 years or more	156	117
	<5 years	160	133
	Total HSDA:	844	637
Total HA:		1354	1051

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	870	670
	5 years or more	254	187
	<5 years	230	194
Total HA:		1354	1051

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	210	957	68	205
NORTH VANCOUVER ISLAND	159	362	32	63
SOUTH VANCOUVER ISLAND	234	2005	42	599
Total:	603	3324	142	867

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	85
NORTH VANCOUVER ISLAND	51
SOUTH VANCOUVER ISLAND	130
Total:	266

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	8	8	7
	35-49	18	21	11
	50+	30	40	16
	Total HSDA:	56	69	34
NORTH WEST	20-34	*	5	*
	35-49	*	38	*
	50+	*	85	*
	Total HSDA:	80	128	67
NORTHERN INTERIOR	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	205	311	157
Total HA:		341	508	258

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		341	508	258

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	115	178	86
Male	226	330	172

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	258	53	590	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	30	16
	5 years or more	9	5
	<5 years	17	13
	Total HSDA:	56	34
NORTH WEST	10 years or more	54	44
	5 years or more	12	10
	<5 years	14	13
	Total HSDA:	80	67
NORTHERN INTERIOR	10 years or more	122	99
	5 years or more	52	33
	<5 years	31	25
	Total HSDA:	205	157
Total HA:		341	258

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	206	159
	5 years or more	73	48
	<5 years	62	51
Total HA:		341	258

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribers in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	39	51	5	7
NORTH WEST	90	170	13	31
NORTHERN INTERIOR	128	519	25	199
Total:	257	740	43	237

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	7
NORTH WEST	28
NORTHERN INTERIOR	23
Total:	58

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	12	5
	KOOTENAY BOUNDARY	6	9	5
	OKANAGAN	32	52	19
	THOMPSON/CARIBOO/SHUSWAP	26	55	16
	Total HA:	70	128	45
FRASER	FRASER EAST	35	52	24
	FRASER NORTH	53	97	42
	FRASER SOUTH	79	118	57
	Total HA:	167	267	123
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	29	56	26
	RICHMOND	6	12	5
	VANCOUVER	431	912	347
	Total HA:	466	980	378
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	49	85	40
	NORTH VANCOUVER ISLAND	16	31	13
	SOUTH VANCOUVER ISLAND	48	97	39
	Total HA:	113	213	92
NORTHERN	NORTH EAST	13	17	10
	NORTH WEST	37	73	32
	NORTHERN INTERIOR	72	124	60
	Total HA:	122	214	102
Total:		938	1802	740

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	602	1162	475
Female	336	640	265

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	740	54	550	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir: a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Antiretroviral: a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla: the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

Cabenuva: the ViiV Healthcare trade name for an injectable formulation containing CABOTEGRAVIR and RILPIVIRINE.

Cabotegravir: an INTEGRASE INHIBITOR.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Complera: the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Descovy: the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.





Monthly Report

Didanosine (Videx): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir: an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine: a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fostemsavir: an ATTACHMENT INHIBITOR from ViiV Healthcare. Fostemsavir is a PRODRUG of TEMSAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa: the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine: a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.





MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Odefsey: the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix: the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.





Monthly Report

Raltegravir (Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Stavudine (Zerit): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq: the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir: the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada: the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

